Vanessa Research, the Hamden Connecticut-based biomedical company producing innovative products for unmet medical needs, announced today that it is changing its name to Vanessa Biotech. The new name is a testament to the company’s exciting evolution. “The company was founded in 2014 and has since transitioned to a global business with multiple offerings in the biotechnology space. The name change not only reflects how much the company has improved as an organization, but also indicates how much we have accomplished, and are capable of, now and in the future,” said Don Janezic, CFO. The company name remains a tribute to Professor Vanessa Ameen, whose research laid the foundation for the company’s innovative flagship product, Shylicine™, the first-ever drug developed to treat the rare and often lethal genetic pediatric disorder known as microvillus inclusion disease (MVID). Shylicine™ currently has orphan drug designation and is in Phase 2 clinical trials through the European Medicine Agency. In addition to a treatment for MVID, Vanessa Biotech is leveraging groundbreaking research to develop other biotechnologies that are currently in the company’s product pipeline. “The company has grown from a small, research-focused organization to a global entity that is actively discovering, developing and commercializing solutions for multiple gastroenterological conditions. While often overlooked, these diseases impact the quality of life of millions of people worldwide. Our name may have changed, but our mission will remain the same, to give hope where none existed,” said Dr. Dmitry Kravtsov, VP Research and Development.
About Vanessa Biotech
Vanessa Biotech is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices, and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain and Germany in addition to its Hamden, Conn. corporate campus.
Vanessa Biotech P.O. Box 185755
Hamden, CT 06518 USA
+1 203 836 8424